ANCN vs. KA, HILS, AIMD, ENVB, ASLN, PULM, LIXT, TENX, YMTX, and ADIL
Should you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Kineta (KA), Hillstream BioPharma (HILS), Ainos (AIMD), Enveric Biosciences (ENVB), ASLAN Pharmaceuticals (ASLN), Pulmatrix (PULM), Lixte Biotechnology (LIXT), Tenax Therapeutics (TENX), Yumanity Therapeutics (YMTX), and Adial Pharmaceuticals (ADIL). These companies are all part of the "medical" sector.
Kineta (NASDAQ:KA) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.
Kineta's return on equity of 36.08% beat Anchiano Therapeutics' return on equity.
Anchiano Therapeutics received 55 more outperform votes than Kineta when rated by MarketBeat users. However, 100.00% of users gave Kineta an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote.
Kineta has higher revenue and earnings than Anchiano Therapeutics. Kineta is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kineta had 2 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 2 mentions for Kineta and 0 mentions for Anchiano Therapeutics. Anchiano Therapeutics' average media sentiment score of 0.43 beat Kineta's score of 0.00 indicating that Kineta is being referred to more favorably in the media.
30.3% of Kineta shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 29.8% of Kineta shares are owned by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Kineta has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
Kineta currently has a consensus price target of $8.00, suggesting a potential upside of 1,468.63%. Given Anchiano Therapeutics' higher possible upside, equities analysts clearly believe Kineta is more favorable than Anchiano Therapeutics.
Summary
Kineta beats Anchiano Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Anchiano Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anchiano Therapeutics Competitors List
Related Companies and Tools
